These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38752519)

  • 1. Social Determinants of Health and Incident Apparent Treatment-Resistant Hypertension Among White and Black US Adults: The REGARDS Study.
    Akinyelure OP; Jaeger BC; Safford MM; Oparil S; Carson AP; Sims A; Hannon L; Howard G; Muntner P; Hardy ST
    J Am Heart Assoc; 2024 May; 13(10):e031695. PubMed ID: 38752519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social Determinants of Health and Uncontrolled Blood Pressure in a National Cohort of Black and White US Adults: the REGARDS Study.
    Akinyelure OP; Jaeger BC; Oparil S; Carson AP; Safford MM; Howard G; Muntner P; Hardy ST
    Hypertension; 2023 Jul; 80(7):1403-1413. PubMed ID: 37082942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care fragmentation and blood pressure control among adults taking antihypertensive medication.
    Colvin CL; Safford MM; Muntner P; Colantonio LD; Kern LM
    Am J Manag Care; 2022 Mar; 28(3):108-115. PubMed ID: 35404546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Apparent Treatment-Resistant Hypertension in the United States.
    Carey RM; Sakhuja S; Calhoun DA; Whelton PK; Muntner P
    Hypertension; 2019 Feb; 73(2):424-431. PubMed ID: 30580690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study.
    Langford AT; Akinyelure OP; Moore TL; Howard G; Min YI; Hillegass WB; Bress AP; Tajeu GS; Butler M; Jaeger BC; Yano Y; Shimbo D; Ogedegbe G; Calhoun D; Booth JN; Muntner P
    Hypertension; 2020 Nov; 76(5):1600-1607. PubMed ID: 32924633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.
    Irvin MR; Sitlani CM; Floyd JS; Psaty BM; Bis JC; Wiggins KL; Whitsel EA; Sturmer T; Stewart J; Raffield L; Sun F; Liu CT; Xu H; Cupples AL; Tanner RM; Rossing P; Smith A; Zilhão NR; Launer LJ; Noordam R; Rotter JI; Yao J; Li X; Guo X; Limdi N; Sundaresan A; Lange L; Correa A; Stott DJ; Ford I; Jukema JW; Gudnason V; Mook-Kanamori DO; Trompet S; Palmas W; Warren HR; Hellwege JN; Giri A; O'donnell C; Hung AM; Edwards TL; Ahluwalia TS; Arnett DK; Avery CL
    Am J Hypertens; 2019 Nov; 32(12):1146-1153. PubMed ID: 31545351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic kidney disease and incident apparent treatment-resistant hypertension among blacks: Data from the Jackson Heart Study.
    Tanner RM; Shimbo D; Irvin MR; Spruill TM; Bromfield SG; Seals SR; Young BA; Muntner P
    J Clin Hypertens (Greenwich); 2017 Nov; 19(11):1117-1124. PubMed ID: 28921875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.
    Tanner RM; Calhoun DA; Bell EK; Bowling CB; Gutiérrez OM; Irvin MR; Lackland DT; Oparil S; McClellan W; Warnock DG; Muntner P
    Am J Kidney Dis; 2014 May; 63(5):781-8. PubMed ID: 24388119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR; Booth JN; Shimbo D; Lackland DT; Oparil S; Howard G; Safford MM; Muntner P; Calhoun DA
    J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults.
    Howard G; Cushman M; Moy CS; Oparil S; Muntner P; Lackland DT; Manly JJ; Flaherty ML; Judd SE; Wadley VG; Long DL; Howard VJ
    JAMA; 2018 Oct; 320(13):1338-1348. PubMed ID: 30285178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.
    Viazzi F; Piscitelli P; Ceriello A; Fioretto P; Giorda C; Guida P; Russo G; De Cosmo S; Pontremoli R;
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
    Egan BM; Zhao Y; Li J; Brzezinski WA; Todoran TM; Brook RD; Calhoun DA
    Hypertension; 2013 Oct; 62(4):691-7. PubMed ID: 23918752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.
    Irvin MR; Shimbo D; Mann DM; Reynolds K; Krousel-Wood M; Limdi NA; Lackland DT; Calhoun DA; Oparil S; Muntner P
    J Clin Hypertens (Greenwich); 2012 Oct; 14(10):694-700. PubMed ID: 23031147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.
    Irvin MR; Booth JN; Sims M; Bress AP; Abdalla M; Shimbo D; Calhoun DA; Muntner P
    J Clin Hypertens (Greenwich); 2018 Mar; 20(3):438-446. PubMed ID: 29436105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.
    Tanner RM; Chaudary N; Colantonio LD; Merriman TR; Reynolds RJ; Bridges SL; Cushman M; Saag K; Limdi N; Muntner P; Howard G; Irvin MR
    J Hypertens; 2023 Jun; 41(6):1033-1039. PubMed ID: 37016935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk.
    Colantonio LD; Booth JN; Bress AP; Whelton PK; Shimbo D; Levitan EB; Howard G; Safford MM; Muntner P
    J Am Coll Cardiol; 2018 Sep; 72(11):1187-1197. PubMed ID: 30189994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Number of Social Determinants of Health and Fatal and Nonfatal Incident Coronary Heart Disease in the REGARDS Study.
    Safford MM; Reshetnyak E; Sterling MR; Richman JS; Muntner PM; Durant RW; Booth J; Pinheiro LC
    Circulation; 2021 Jan; 143(3):244-253. PubMed ID: 33269599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive Protein and Incident Hypertension in Black and White Americans in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort Study.
    Plante TB; Long DL; Guo B; Howard G; Carson AP; Howard VJ; Judd SE; Jenny NS; Zakai NA; Cushman M
    Am J Hypertens; 2021 Aug; 34(7):698-706. PubMed ID: 33326556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.